Skip to main content
Log in

Sarkoidose getriggert durch Immuncheckpoint-Blockade

Sarcoidosis triggered by immune checkpoint blockade

  • Diaklinik
  • Published:
Der Hautarzt Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Abbreviations

ACE:

Angiotensin-konvertierendes Enzym

PD1:

Programmed cell death protein 1

PD-L1:

Programmed cell death ligand 1

Tg-AK:

Thyreoglobulin-Antikörper

TPO-AK:

Thyreoperoxidase-Antikörper

TRAK:

Thyreotropin‐Rezeptor‐Autoantikörper

TSH:

Thyreoidea-stimulierendes Hormon

Literatur

  1. Braun NA, Celada LJ, Herazo-Maya JD et al (2014) Blockade of the programmed death-1 pathway restores sarcoidosis CD4(+) T‑cell proliferative capacity. Am J Respir Crit Care Med 190:560–571

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  2. Eckert A, Schoeffler A, Dalle S et al (2009) Anti-CTLA4 monoclonal antibody induced sarcoidosis in a metastatic melanoma patient. Dermatology 218:69–70

    Article  PubMed  CAS  Google Scholar 

  3. Heinzerling LM, Anliker MD, Muller J et al (2010) Sarcoidosis induced by interferon-alpha in melanoma patients: incidence, clinical manifestations, and management strategies. J Immunother 33:834–839

    Article  PubMed  CAS  Google Scholar 

  4. Murphy KP, Kennedy MP, Barry JE et al (2014) New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment. Oncol Res Treat 37:351–353

    Article  PubMed  CAS  Google Scholar 

  5. Reule RB, North JP (2013) Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab. J Am Acad Dermatol 69:e272–e273

    Article  PubMed  Google Scholar 

  6. Reuss JE, Kunk PR, Stowman AM et al (2016) Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature. J Immunother Cancer 4:94

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Markus Heppt M.Sc..

Ethics declarations

Interessenkonflikt

M. Heppt erhielt Vortragshonorare und/oder Beratungshonorare und/oder Reiseunterstützung von Novartis, Roche, BMS und MSD. C. Berking erhielt Vortragshonorare und/oder Beratungshonorare und/oder Reiseunterstützung von Amgen, AstraZeneca, BMS, Merck, MSD, Novartis, Pierre Fabre, Regeneron, Roche, und Sanofi-Aventis. A.‑C. Niesert und M. Flaig geben an, dass kein Interessenskonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren. Alle Patienten, die über Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts zu identifizieren sind, haben hierzu ihre schriftliche Einwilligung gegeben.

This article is part of a supplement sponsored by LEO Pharma GmbH.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Heppt, M., Niesert, AC., Flaig, M. et al. Sarkoidose getriggert durch Immuncheckpoint-Blockade. Hautarzt 69 (Suppl 1), 11–13 (2018). https://doi.org/10.1007/s00105-018-4186-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00105-018-4186-6

Navigation